Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative agerelated macular degeneration. BRAMD

被引：0
|
作者：
Schauwvlieghe, Ann-Sofie Marie Evelyn [1 ]
Dijkman, Greetje [2 ]
Hooymans, Johanna M. M. [3 ]
Verbraak, Frank D. [1 ,4 ]
Dijkgraaf, Marcel G. [5 ]
Peto, Tunde [6 ,7 ]
Vingerling, Johannes R. [8 ,9 ]
Hoyng, Carel [10 ]
Schlingemann, Reinier O. [1 ,11 ]
机构：
[1] Univ Amsterdam, Acad Med Ctr, Ophthalmol, Amsterdam, Netherlands
[2] Leiden Univ, Med Ctr, Ophthalmol, Leiden, Netherlands
[3] Univ Med Ctr Groningen, Ophthalmol, Groningen, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Biomed Engn & Phys, Amsterdam, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Clin Res Unit, Amsterdam, Netherlands
[6] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England
[7] UCL Inst Ophthalmol, London, England
[8] Erasmus MC, Ophthalmol, Rotterdam, Netherlands
[9] Erasmus MC, Epidemiol, Rotterdam, Netherlands
[10] Radboud Univ Nijmegen Med Ctr, Ophthalmol, Nijmegen, Netherlands
[11] Netherlands Inst Neurosci, Amsterdam, Netherlands
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2014年 / 55卷 / 13期
关键词：
412 age-related macular degeneration; 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials; 748 vascular endothelial growth factor;
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
870
引用
收藏
页数：3
相关论文
共 50 条
  • [41] DELAY IN RANIBIZUMAB INJECTIONS FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
    Wang, Bob
    Lake, Stewart
    Saha, Niladri
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2010, 38 : 8 - +
  • [42] Efficacy of Extended Interval Bevacizumab Therapy in Exudative Macular Degeneration
    Manry, Matthew
    Allison, James
    Comer, Grant Michael
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [43] AGE RELATED MACULAR DEGENERATION Cost comparison of ranibizumab and bevacizumab
    Jackson, Timothy L.
    Kirkpatrick, Lucy
    BMJ-BRITISH MEDICAL JOURNAL, 2011, 343
  • [44] Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?
    Harvey, Ken J.
    Day, Richard
    Campbell, William G.
    Lipworth, Wendy
    MEDICAL JOURNAL OF AUSTRALIA, 2011, 194 (11) : 567 - 568
  • [45] Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
    Koike, Naoko
    Otsuji, Tsuyoshi
    Tsumura, Akiko
    Miki, Katsuaki
    Sakai, Yukio
    Nishimura, Tetsuya
    Takahashi, Kanji
    CLINICAL OPHTHALMOLOGY, 2019, 13 : 1247 - 1251
  • [46] Choroidal thickness in exudative agerelated macular degeneration and influence of intravitreal anti-VEGF treatment
    Rodrigues, Rita
    Moleiro, Ana
    Carneiro, Angela
    Falcao, Manuel
    ACTA OPHTHALMOLOGICA, 2022, 100
  • [47] OCT angiography for exudative age-related macular degeneration. Initial experiences
    Lommatzsch, A.
    Farecki, M. -L.
    Book, B.
    Heimes, B.
    Pauleikhoff, D.
    OPHTHALMOLOGE, 2016, 113 (01): : 23 - 29
  • [48] Evaluation of imaging examinations for decision of retreatment in exudative age related macular degeneration.
    Srour, Mayer
    Tilleul, Julien
    Massamba, Nathalie
    Ghardaoui, Farah
    Boulanger-Scemama, Elise
    Lalloum, Franck
    Querques, Giuseppe
    Souied, Eric H.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [49] Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
    Jun Li
    Han Zhang
    Peng Sun
    Feng Gu
    Zhe-Li Liu
    International Journal of Ophthalmology, 2013, (02) : 169 - 173
  • [50] Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
    Li, Jun
    Zhang, Han
    Sun, Peng
    Gu, Feng
    Liu, Zhe-Li
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2013, 6 (02) : 169 - 173
12345